Additionally, a meta-analysis of randomized controlled trials (RCTs)assessing the safety and efficacy of GLP-1 and Gcg RAs, including cotadutide,found that these agents significantly reduced body weight and improved glycemiccontrol in individuals with T2D and obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.